Mode
Text Size
Log in / Sign up
N/A N=197 Treatment

Model 4396 Left Ventricular (LV) Lead Study

Heart Failure

Enrolled (actual)
197
Serious AEs
38.6%
Results posted
Dec 2011
Primary outcome: Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Pacing Lead (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Primary completion
Jul 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety (Subjects Without a Model 4396 Lead Related Complication)
155
PRIMARY
Efficacy: Distal Tip Electrode Voltage Threshold
1.6
PRIMARY
Efficacy: Proximal Ring Voltage Threshold
2.3
SECONDARY
Subjects Successfully Implanted With Model 4396 Lead
152
SECONDARY
Subjects Successfully Implanted With Any Transvenous LV Lead After Cannulation
185
SECONDARY
Subjects Successfully Implanted With Any Transvenous LV Lead
185
SECONDARY
Subjects Successfully Implanted With Any Medtronic Attain Family LV Lead
183
SECONDARY
Cannulation Time
6.1
SECONDARY
Fluoroscopy Time
20.6
SECONDARY
Model 4396 Lead Placement Time
13.9
SECONDARY
Total Operation Time
97.4
SECONDARY
Assessment of Lead Handling Characteristics Reported as Acceptable
162
SECONDARY
Efficacy: Bipolar Voltage Threshold
2.4
SECONDARY
Characterize Model 4396 Electrical Performance- Tip Electrode: Voltage Threshold
1.5
SECONDARY
Characterize Model 4396 Electrical Performance- Tip Electrode: Pacing Impedance
571.2
SECONDARY
Characterize Model 4396 Electrical Performance- Tip Electrode: Sensing
18.3
SECONDARY
Characterize Model 4396 Electrical Performance- Ring Electrode: Voltage Threshold
2.2
SECONDARY
Characterize Model 4396 Electrical Performance- Ring Electrode: Pacing Impedance
544.8
SECONDARY
Characterize Model 4396 Electrical Performance- Ring Electrode: Sensing
17.6
SECONDARY
Characterize Model 4396 Electrical Performance- Bipolar Configuration: Voltage Threshold
2.4
SECONDARY
Characterize Model 4396 Electrical Performance- Bipolar Configuration: Pacing Impedance
967.1
SECONDARY
Characterize Model 4396 Electrical Performance- Bipolar Configuration: Sensing
15.0

Summary

This study is designed to show that a new lead, which paces the left bottom chamber (left ventricle) of the heart, is safe and effective. Using a lead on the left side of the heart has been shown to potentially improve heart failure symptoms. The shape and size of this new lead may make it a good choice for patients or physicians.

Eligibility Criteria

Inclusion Criteria

  • CRT/Cardiac Resynchronization Therapy-Defibrillator (CRT-D) indications, New York Heart Association (NYHA) III and IV, indicated for implantable cardiac defibrillator (ICD) if CRT-D is implanted, patient consent, geographically stable

Exclusion Criteria

  • LV lead implant attempt in last 30 days, unstable angina or acute myocardial infarction (MI) in past 30 days, coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) in past 3 months, contraindicated for transvenous pacing, heart transplant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00853593). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search